193 related articles for article (PubMed ID: 38528576)
1. Prospective virtual screening combined with bio-molecular simulation enabled identification of new inhibitors for the KRAS drug target.
Ajmal A; Alkhatabi HA; Alreemi RM; Alamri MA; Khalid A; Abdalla AN; Alotaibi BS; Wadood A
BMC Chem; 2024 Mar; 18(1):57. PubMed ID: 38528576
[TBL] [Abstract][Full Text] [Related]
2. In Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches.
Ajmal A; Danial M; Zulfat M; Numan M; Zakir S; Hayat C; Alabbosh KF; Zaki MEA; Ali A; Wei D
Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794122
[TBL] [Abstract][Full Text] [Related]
3. Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRAS
Luo L; Zheng T; Wang Q; Liao Y; Zheng X; Zhong A; Huang Z; Luo H
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631410
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.
Oyedele AK; Ogunlana AT; Boyenle ID; Ibrahim NO; Gbadebo IO; Owolabi NA; Ayoola AM; Francis AC; Eyinade OH; Adelusi TI
Mol Divers; 2023 Aug; 27(4):1795-1807. PubMed ID: 36271195
[TBL] [Abstract][Full Text] [Related]
5. Prediction of KRAS
Srisongkram T; Khamtang P; Weerapreeyakul N
J Mol Graph Model; 2023 Jul; 122():108466. PubMed ID: 37058997
[TBL] [Abstract][Full Text] [Related]
6. Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study.
Srisongkram T; Weerapreeyakul N
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614109
[TBL] [Abstract][Full Text] [Related]
7. Machine Learning-based Virtual Screening for STAT3 Anticancer Drug Target.
Wadood A; Ajmal A; Junaid M; Rehman AU; Uddin R; Azam SS; Khan AZ; Ali A
Curr Pharm Des; 2022; 28(36):3023-3032. PubMed ID: 35909285
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel peptide inhibitors for the KRas-G12C variant to prevent oncogenic signaling.
Ajmal A; Ali Y; Khan A; Wadood A; Rehman AU
J Biomol Struct Dyn; 2023; 41(18):8866-8875. PubMed ID: 36300526
[TBL] [Abstract][Full Text] [Related]
9. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking analysis reveals differential binding affinities of multiple classes of selective inhibitors towards cancer-associated KRAS mutants.
Mullaguri SC; Akula S; Sahoo PS; Ashireddygari VR; Mupparapu V; Silveri R; Prasad Burra VLS; Kancha RK
3 Biotech; 2022 Dec; 12(12):343. PubMed ID: 36353445
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
[TBL] [Abstract][Full Text] [Related]
12. Covalent inhibitor targets KRas
Li HY; Qi WL; Wang YX; Meng LH
Genes Dis; 2023 Mar; 10(2):403-414. PubMed ID: 37223497
[No Abstract] [Full Text] [Related]
13. Adagrasib: a novel inhibitor for
Guo MZ; Marrone KA; Spira A; Rosner S
Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
[TBL] [Abstract][Full Text] [Related]
14. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
15. The KRAS-G12C inhibitor: activity and resistance.
Liu J; Kang R; Tang D
Cancer Gene Ther; 2022 Jul; 29(7):875-878. PubMed ID: 34471232
[TBL] [Abstract][Full Text] [Related]
16. Targeting
Désage AL; Léonce C; Swalduz A; Ortiz-Cuaran S
Front Oncol; 2022; 12():796832. PubMed ID: 35251972
[TBL] [Abstract][Full Text] [Related]
17. Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C.
Yang W; Ge J; Yuan M; Li J; Pan L; Ren J; Dou G; Yang L; Zhou Y; Xie H; Wang X; Hu H
Anticancer Drugs; 2023 Jun; 34(5):609-619. PubMed ID: 36847041
[TBL] [Abstract][Full Text] [Related]
18. Targeting KRAS in Non-Small Cell Lung Cancer.
Corral de la Fuente E; Olmedo Garcia ME; Gomez Rueda A; Lage Y; Garrido P
Front Oncol; 2021; 11():792635. PubMed ID: 35083149
[TBL] [Abstract][Full Text] [Related]
19. Flavonoids as potential KRAS inhibitors: DFT, molecular docking, molecular dynamics simulation and ADMET analyses.
Prinsa ; Saha S; Bulbul MZH; Ozeki Y; Alamri MA; Kawsar SMA
J Asian Nat Prod Res; 2024 Apr; ():1-38. PubMed ID: 38647682
[TBL] [Abstract][Full Text] [Related]
20. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
